About this Research Topic
The adoptive transfer of chimeric antigen receptor (CAR) T-cells has achieved remarkable therapeutic responses in patients with certain haematological malignancies and recent clinical studies reveal meaningful outcomes against some solid tumor-types. Over the years, important advances have been made to improve CAR T-cell therapy, including the development of advanced gene-engineering tools, remote-controlled and logic-gated CAR designs, and strategies to prolong CAR T-cell persistence, to harness endogenous immunity, and to resist T-cell exhaustion and overcome barriers in the tumor microenvironment. A variety of CAR T-cell co-engineering strategies and combinatorial treatment approaches are demonstrating promise in the clinic, as well as CAR-engineered macrophages and NK cells. Remarkably, CAR T-cell therapy may hold even greater potential in the treatment of autoimmune, cardiovascular, and infectious diseases. Indeed, early clinical studies suggest that CAR T-cells can send autoimmune disorders into remission with fewer side effects, like cytokine release syndrome and neurotoxicity, as commonly seen in treated cancer patients. This is truly an extraordinary time to be working in the field of immune cell engineering for treating human diseases!
In this Research Topic, we invite submissions in CAR design, the development of gene engineering tools and novel strategies for improving the efficacy and safety of immune cell therapy of cancer and other diseases. Article types accepted include Original Research, Brief Research Report, Review and Mini Review, Opinion and Perspective.
In this Research Topic, we invite submissions in CAR design, the development of gene engineering tools and novel strategies for improving the efficacy and safety of immune cell therapy of cancer and other diseases. Article types accepted include Original Research, Brief Research Report, Review and Mini Review, Opinion and Perspective.
Keywords: CAR engineering, Immune cells, Solid cancers, TME (tumor microenvironment), Therapeutic applications, Preclinical development, cancer, Chimeric Antigen Receptor, CAR, Immuno-Engineering, Gene-Engineering, Rare Diseases, T lymphocytes, NK Cells, Macrophages
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
